S100B and chronic myelogenous leukemia, BCR-ABL1 positive: It inhibits the interactions between RAGE and its ligands, including Aβ1-42, HMGB1 (high mobility group box 1), S100B, and CML (chronic myeloid leukemia) (Cummings et al., 2020).